Drug Profile

West Nile virus vaccine - Sanofi

Alternative Names: ChimeriVax-West Nile; ChimeriVax-WN02

Latest Information Update: 08 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Acambis
Class Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Suspended West Nile virus infections

Most Recent Events

25 Sep 2008 Acambis has been acquired by sanofi pasteur
13 Nov 2007 Acambis and sanofi pasteur enter into an exclusive global collaboration agreement for the West Nile virus vaccine
12 Sep 2006 Immunogenicity and adverse event data from a phase II trial released by Acambis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com